CEBPA and intrahepatic cholangiocarcinoma: Rather than the previous requirement for biallelic CEBPA abnormalities, the recent finding of favorable outcome of in-frame bZIP-mutation irrespective of double or single CEBPA-mutated status [12–14] has been adapted in both ICC and the 2022 ELN recommendation, while WHO-5 continues to include both CEBPAdm or bZIP CEBPA mutation[19, 20, 72].